Avid Bioservices Inc (CDMO)

[biopharm]

However, just like with our mayonnaise immuno-therapy needs some GENERIC component to allow these anti-body combinations to be effective at their maximum. What is needed is what is called the conditioning of the tumour environment. It becomes more clear every day that the general MOA of the combo's is to 'light up' the problems in order for the immune system to kick in and take care of it. This can be dome by preventing the problem to be masked and remain invisible from the immune system or by attracting the attention of the immune system to a problem that would otherwise not be anyways visible.
...
...


We all know that this game, actually real war although some on here may not experience it that way, is all about getting approved and becoming SOC so that insurance and social security include the drug in their pay-back programs. And to become SOC you must beat the previous SOC.

Is it still time for Roche to occupy the Bavituximab field now that not only AstraZeneca but also Merck are clearly involved in it and now that the NCCN members are going to run several clinical trials and Memorial Sloan Kettering is working with the drug? What can they achieve? Getting approximately the SAME results as the other PD/CTLA combinations with bavituximab but then much later because the others will again have established SOC before them because they are already on the program. It looks to me that Roche/Genetech has that T-shirt already today in the mono-therapy I-O war where they ended at the best on the 3rd place after BMY/MERCK. It kind of illustrates GILD's CEO statement about BP latency.

Is Roche going to let that happen AGAIN? Probably not, this I-O market will dominate the oncology segment, and possible others, for at least a decade.
...
...

Yes, I doubt Roche has showed their hands yet...but Anita Kavlie ...has.

If one really reviews the timeline of patents between Peregrine and Omeros and Roche, something bigger awaits and if I was Roche maybe they wait till lots of other Big Pharma have spent Billions before they show their hands and others involved

________



Patents by Inventor Anita Kavlie
Anita Kavlie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Compositions for Inhibiting MASP-2 Dependent Complement Activation
Publication number: 20190119402
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Type: Application
Filed: July 13, 2018
Publication date: April 25, 2019
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov



ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
Publication number: 20180282404
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: February 28, 2018
Publication date: October 4, 2018
Applicant: Hoffmann-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer




Compositions for inhibiting MASP-2 dependent complement activation
Patent number: 10047165
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Type: Grant
Filed: September 13, 2016
Date of Patent: August 14, 2018
Assignee: Omeros Corporation
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov








BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
Publication number: 20170369566
Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: May 23, 2017
Publication date: December 28, 2017
Applicant: Hoffmann-La Roche Inc.
Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas










BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
Publication number: 20170240626
Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type: Application
Filed: October 4, 2016
Publication date: August 24, 2017
Applicant: Hoffmann-La Roche Inc.
Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas








Bispecific anti-VEGF/anti-ANG-2 antibodies
Patent number: 9708396
Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Grant
Filed: February 27, 2014
Date of Patent: July 18, 2017
Assignee: HOFFMANN-LA ROCHE INC.
Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas









COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
Publication number: 20170088632
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
Type: Application
Filed: September 13, 2016
Publication date: March 30, 2017
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov










ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
Publication number: 20170029493
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: April 12, 2016
Publication date: February 2, 2017
Applicant: Hoffmann-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer











Compositions for inhibiting MASP-2 dependent complement activation
Patent number: 9475885
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Type: Grant
Filed: March 17, 2015
Date of Patent: October 25, 2016
Assignee: Omeros Corporation
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov









ANTIBODIES
Publication number: 20160244527
Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Type: Application
Filed: May 11, 2016
Publication date: August 25, 2016
Applicant: AFFITECH RESEARCH AS
Inventors: Anita KAVLIE, Sergej Michailovic KIPRIJANOV











Anti-VEGF antibody compositions and methods
Patent number: 9421256
Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.

Type: Grant
Filed: February 15, 2013
Date of Patent: August 23, 2016
Assignees: Affitech Research AS, Peregrine Pharmaceuticals, Inc.
Inventors: Anita Kavlie, Kyle Schlunegger









Antibodies
Patent number: 9353185
Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Type: Grant
Filed: May 16, 2014
Date of Patent: May 31, 2016
Assignee: AFFITECH RESEARCH AS
Inventors: Anita Kavlie, Sergej Michailovi{hacek over (c)} Kiprijanov










Antibodies against human angiopoietin 2
Patent number: 9340609
Abstract: The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6.

Type: Grant
Filed: December 4, 2012
Date of Patent: May 17, 2016
Assignee: Hoffmann-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer










COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
Publication number: 20160002349
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Type: Application
Filed: March 17, 2015
Publication date: January 7, 2016
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov










ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
Publication number: 20150284457
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: June 4, 2015
Publication date: October 8, 2015
Applicant: HOFFMANN-LA ROCHE INC.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer








Antibodies against human angiopoietin 2
Patent number: 9109027
Abstract: The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).

Type: Grant
Filed: July 13, 2012
Date of Patent: August 18, 2015
Assignee: Hoffman-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer









BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG2 ANTIBODIES
Publication number: 20150191535
Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: December 15, 2014
Publication date: July 9, 2015
Applicant: HOFFMANN-LA ROCHE INC.
Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas









Antibodies against human angiopoietin 2
Patent number: 9073986
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Grant
Filed: February 6, 2013
Date of Patent: July 7, 2015
Assignee: Hoffman-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
Compositions for inhibiting MASP-2 dependent complement activation
Patent number: 9011860
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Type: Grant
Filed: May 4, 2012
Date of Patent: April 21, 2015
Assignee: Omeros Corporation
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov









Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies
Patent number: 8945552
Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Grant
Filed: March 24, 2011
Date of Patent: February 3, 2015
Assignee: Hoffmann-La Roche Inc.
Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas, Wolfgang Schaefer, Kay-Gunnar Stubenrauch, Markus Thomas

Patents by Inventor Anita Kavlie
Anita Kavlie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).











BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
Publication number: 20150004166
Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: February 27, 2014
Publication date: January 1, 2015
Applicant: HOFFMANN-LA ROCHE INC.
Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
Antibodies
Publication number: 20140369925
Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Type: Application
Filed: May 16, 2014
Publication date: December 18, 2014
Applicant: AFFITECH RESEARCH AS
Inventors: Anita Kavlie, Sergej Michailovic Kiprijanov
Isolated antibodies which bind to CXC chemokine receptor 4
Patent number: 8748107
Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Type: Grant
Filed: February 10, 2011
Date of Patent: June 10, 2014
Assignee: Affitech Research AS
Inventors: Anita Kavlie, Sergej Michailovic Kiprijanov










Bispecific anti-VEGF/anti-ANG-2 antibodies
Patent number: 8703130
Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Grant
Filed: August 9, 2012
Date of Patent: April 22, 2014
Assignee: Hoffmann-La Roche, Inc.
Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas










ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
Publication number: 20140065151
Abstract: The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).

Type: Application
Filed: July 13, 2012
Publication date: March 6, 2014
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
Antibodies against human angiopoietin 2
Patent number: 8399626
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Grant
Filed: January 26, 2012
Date of Patent: March 19, 2013
Assignee: Hoffmann-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer












Anti-VEGF antibody compositions and methods
Patent number: 8394943
Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.

Type: Grant
Filed: September 6, 2011
Date of Patent: March 12, 2013
Assignees: Affitech Research AS, Peregrine Pharmaceuticals, Inc.
Inventors: Anita Kavlie, Kyle Schlunegger












Antibodies against human angiopoietin 2
Patent number: 8361747
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Grant
Filed: January 26, 2012
Date of Patent: January 29, 2013
Assignee: Hoffmann-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer










BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
Publication number: 20120321627
Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: August 9, 2012
Publication date: December 20, 2012
Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas












COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
Publication number: 20120282263
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
Type: Application
Filed: May 4, 2012
Publication date: November 8, 2012
Applicant: OMEROS CORPORATION
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov











Bispecific anti-VEGF/anti-ANG-2 antibodies
Patent number: 8268314
Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Grant
Filed: October 2, 2009
Date of Patent: September 18, 2012
Assignee: Hoffmann-La Roche Inc.
Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas









Antibodies Against Human Angiopoietin 2
Publication number: 20120141500
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: January 26, 2012
Publication date: June 7, 2012
Inventors: ULRICH BRINKMANN, REMKO ALBERT GRIEP, KLAUS KALUZA, ANITA KAVLIE, CHRISTIAN KLEIN, JOERG THOMAS REGULA, WERNER SCHEUER








Antibodies Against Human Angiopoietin 2
Publication number: 20120142091
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type: Application
Filed: January 26, 2012
Publication date: June 7, 2012
Inventors: ULRICH BRINKMANN, REMKO ALBERT GRIEP, KLAUS KALUZA, ANITA KAVLIE, CHRISTIAN KLEIN, JOERG THOMAS REGULA, WERNER SCHEUER










Anti-VEGF Antibody Compositions and Methods
Publication number: 20120064001
Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.

Type: Application
Filed: September 6, 2011
Publication date: March 15, 2012
Applicants: AFFITECH RESEARCH AS, PEREGRINE PHARMACEUTICALS, INC.
Inventors: Anita Kavlie, Kyle Schlunegger










Antibodies against human angiopoietin 2
Patent number: 8133979
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Grant
Filed: December 11, 2009
Date of Patent: March 13, 2012
Assignee: Hoffmann-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer












Antibodies
Publication number: 20110311449
Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Type: Application
Filed: February 10, 2011
Publication date: December 22, 2011
Applicant: AFFITECH RESEARCH AS
Inventors: Anita Kavlie, Sergej Michailovic Kiprijanov
Anti-VEGF antibody compositions and methods
Patent number: 8034905
Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.

Type: Grant
Filed: November 7, 2008
Date of Patent: October 11, 2011
Assignees: Affitech Research, AS, Peregrine Pharmaceuticals, Inc.
Inventors: Anita Kavlie, Kyle Schlunegger













BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
Publication number: 20110236388
Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: March 24, 2011
Publication date: September 29, 2011
Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas












ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
Publication number: 20100159587
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: December 11, 2009
Publication date: June 24, 2010
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer













BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
Publication number: 20100111967
Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: October 2, 2009
Publication date: May 6, 2010
Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas